IL80231A - Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors - Google Patents

Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors

Info

Publication number
IL80231A
IL80231A IL80231A IL8023186A IL80231A IL 80231 A IL80231 A IL 80231A IL 80231 A IL80231 A IL 80231A IL 8023186 A IL8023186 A IL 8023186A IL 80231 A IL80231 A IL 80231A
Authority
IL
Israel
Prior art keywords
human breast
diagnosis
hybridomas producing
tumors
breast cancer
Prior art date
Application number
IL80231A
Other languages
English (en)
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of IL80231A publication Critical patent/IL80231A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Navigation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL80231A 1985-10-07 1986-10-03 Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors IL80231A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78507685A 1985-10-07 1985-10-07
US06/786,948 US4938948A (en) 1985-10-07 1985-10-11 Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies

Publications (1)

Publication Number Publication Date
IL80231A true IL80231A (en) 1991-08-16

Family

ID=27120360

Family Applications (1)

Application Number Title Priority Date Filing Date
IL80231A IL80231A (en) 1985-10-07 1986-10-03 Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors

Country Status (13)

Country Link
US (1) US4938948A (de)
EP (1) EP0220858B1 (de)
JP (3) JP2968474B2 (de)
AT (1) ATE85652T1 (de)
AU (1) AU6356986A (de)
CA (1) CA1338706C (de)
DE (1) DE3687736T2 (de)
DK (1) DK478886A (de)
ES (1) ES2053440T3 (de)
FI (1) FI864037L (de)
IL (1) IL80231A (de)
NO (1) NO863974L (de)
NZ (1) NZ217829A (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US7255851B2 (en) * 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
DE10141937A1 (de) * 2001-08-28 2003-03-27 Alfred Schmidt Markierung der Aromatase
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
EP1501855A4 (de) * 2002-03-21 2006-02-22 Sagres Discovery Inc Neue zusammensetzungen und verfahren bei krebs
EP1636561B1 (de) 2002-07-15 2011-02-09 Board Of Regents, The University Of Texas System Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP2058408A3 (de) 2003-02-14 2009-09-09 Sagres Discovery, Inc. Therapeutische GPCR-Targets für Karzinome
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
US20050214286A1 (en) * 2004-01-27 2005-09-29 University Of Southern California Polymer-bound antibody cancer therapeutic agent
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
CN101043891A (zh) 2004-09-18 2007-09-26 巴尔的摩马里兰大学 靶向NCCa－ATP通道的治疗剂及其使用方法
CA2580606A1 (en) 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
SI2645106T2 (sl) 2005-04-04 2025-05-30 Biogen Ma Inc. Metode za ocenjevanje imunskega odziva na terapevtsko sredstvo
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
US8124351B2 (en) 2005-11-18 2012-02-28 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
CN101505795B (zh) 2006-07-03 2013-02-13 查尔斯·戴维·阿代尔 用于调节细胞粘附分子表达的组合物
US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
CA2685675C (en) 2007-05-01 2016-02-16 Research Development Foundation Immunoglobulin fc libraries
WO2009014835A2 (en) 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
AU2008284015B2 (en) 2007-08-03 2014-05-15 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
KR101588736B1 (ko) 2008-01-10 2016-01-26 리서치 디벨롭먼트 파운데이션 얼리키아 샤피엔시스에 대한 백신 및 진단제
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
JP5805538B2 (ja) 2008-11-07 2015-11-04 リサーチ ディベロップメント ファウンデーション Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法
EP2370092A1 (de) 2008-12-03 2011-10-05 Research Development Foundation Modulierung von olfml-3-vermittelter angiogenese
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2485762B1 (de) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4-assays
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
EP2637692A4 (de) 2010-11-12 2014-09-10 Scott & White Healthcare Antikörper gegen den endothelialen tumormarker 8
JP6228014B2 (ja) 2011-02-07 2017-11-08 リサーチ ディベロップメント ファウンデーション 操作された免疫グロブリンＦｃポリペプチド
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
WO2013022599A1 (en) 2011-08-05 2013-02-14 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
EP2744517B1 (de) 2011-08-15 2019-03-13 The University of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern gegen das staphylokokken-protein a
RS58910B1 (sr) 2012-03-20 2019-08-30 Biogen Ma Inc Antitela koja neutrališu virus jcv
HK1207321A1 (en) 2012-04-26 2016-01-29 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2013169377A1 (en) 2012-05-10 2013-11-14 Massachusetts Institute Of Technology Agents for influenza neutralization
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2912064B1 (de) 2012-10-24 2019-04-24 Research Development Foundation Jam-c-antikörper und verfahren zur behandlung von krebs
US9388397B2 (en) 2013-02-15 2016-07-12 Research Development Foundation Deimmunized gelonin molecules and therapies
WO2014144666A2 (en) 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
PT3524617T (pt) 2013-03-15 2023-07-12 Gladiator Biosciences Inc Domínios gla como agentes terapêuticos
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
JP6566941B2 (ja) 2013-06-28 2019-08-28 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 多発性硬化症のための樹状細胞ａｓｇｐｒ標的化免疫治療薬
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
WO2015070009A2 (en) 2013-11-08 2015-05-14 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
EP3094652B1 (de) 2014-01-13 2021-09-29 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
ES2794088T3 (es) 2014-01-29 2020-11-17 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD)
CA2938495A1 (en) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
JP6875129B2 (ja) 2014-05-08 2021-05-19 ノボダイアックス， インコーポレイテッド 直接的な免疫組織化学アッセイ
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
KR102485788B1 (ko) 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
JP6724023B2 (ja) 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
EP3262411B1 (de) 2015-02-25 2022-04-06 Vanderbilt University Antikörper-vermittelte neutralisierung von marburg-virus
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
CA3004438A1 (en) 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
EP3383418B1 (de) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2-peptide für immuntherapie
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
ES2973870T3 (es) 2016-03-29 2024-06-24 Univ Texas Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
EP3478162B1 (de) 2016-07-01 2025-03-19 The General Hospital Corporation Granzym-b-gerichtete bildgebung und therapie
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
EP3534953A4 (de) 2016-11-02 2020-10-07 Vanderbilt University Humane zirka-virus-antikörper und verfahren zur verwendung davon
US11241511B2 (en) 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
US10908168B2 (en) 2017-01-31 2021-02-02 Vanderbilt University Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
EP3652537A4 (de) 2017-05-05 2021-10-20 Memorial Sloan Kettering Cancer Center Technologien zur modularen selbstmontage/-demontage (sada)
WO2018222689A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
CN121609797A (zh) 2017-06-06 2026-03-06 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
BR112020003533A2 (pt) 2017-08-25 2020-11-17 Five Prime Therapeutics, Inc. anticorpos b7-h4 e métodos de uso dos mesmos
PE20201462A1 (es) 2017-09-05 2020-12-17 Gladiator Biosciences Inc Metodo de direccionamiento de exosomas
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
JP2020536855A (ja) 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
KR102823603B1 (ko) 2017-10-12 2025-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 t 세포 수용체
US11851478B2 (en) 2018-01-05 2023-12-26 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
EP3759142A1 (de) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4-antikörper und verfahren zur verwendung davon
EP3768726B1 (de) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Antikörper mit doppelter spezifität für pd-l1 und pd-l2 und verwendungsverfahren dafür
JP7514765B2 (ja) 2018-03-23 2024-07-11 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法
AU2019339469A1 (en) 2018-09-13 2021-03-11 Immune-Onc Therapeutics, Inc. Novel LILRB4 antibodies and uses thereof
WO2020092969A1 (en) 2018-11-02 2020-05-07 Oklahoma Medical Research Foundation Monoclonal antibodies to eltd1 and uses thereof
JP7478149B2 (ja) 2018-11-28 2024-05-02 オレゴン ヘルス アンド サイエンス ユニバーシティー 治療用第ｘｉｉ因子抗体
WO2020167989A1 (en) 2019-02-13 2020-08-20 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
AU2020317009A1 (en) 2019-07-19 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors containing Glypican 2 binding domains
US12410241B2 (en) 2019-07-26 2025-09-09 Vanderbilt University Human monoclonal antibodies to enterovirus D68
EP4041767A1 (de) 2019-09-26 2022-08-17 StCube & Co. Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
AU2021220847A1 (en) 2020-02-11 2022-09-01 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
EP4107173A1 (de) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Verfahren zur expansion tumorinfiltrierender lymphozyten und deren verwendung
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
DK4045533T5 (da) 2020-03-26 2024-07-29 Univ Vanderbilt Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
US20240101667A1 (en) 2020-12-03 2024-03-28 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
US20240165256A1 (en) 2021-03-08 2024-05-23 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
CA3246648A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual-specificity antibodies directed against human PD-L1 and PD-L2 and their methods of use
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
CN121152801A (zh) 2023-03-16 2025-12-16 英脉生物医药(杭州)有限公司 靶向ilt7的抗体和其用途
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
AU2024252135A1 (en) 2023-04-11 2025-11-27 Sterling Ip Pte. Ltd. Treatment of haematological cancer
WO2026044000A1 (en) 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
WO1985001442A1 (en) * 1983-09-28 1985-04-11 Summa Medical Corporation Lectin composition and method for diagnosis of cancer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0160446B1 (de) * 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Brusttumorassoziiertes Antigen und monoklonale Antikörper dazu
US4695538A (en) * 1984-06-01 1987-09-22 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Also Published As

Publication number Publication date
FI864037A7 (fi) 1987-04-08
NZ217829A (en) 1989-06-28
JP2000000092A (ja) 2000-01-07
CA1338706C (en) 1996-11-12
AU6356986A (en) 1987-04-09
JP2000000091A (ja) 2000-01-07
EP0220858B1 (de) 1993-02-10
US4938948A (en) 1990-07-03
JPH08266273A (ja) 1996-10-15
DK478886A (da) 1987-04-08
DE3687736T2 (de) 1993-05-27
FI864037L (fi) 1987-04-08
EP0220858A2 (de) 1987-05-06
NO863974D0 (no) 1986-10-06
ATE85652T1 (de) 1993-02-15
DE3687736D1 (de) 1993-03-25
DK478886D0 (da) 1986-10-07
EP0220858A3 (en) 1988-08-03
FI864037A0 (fi) 1986-10-06
JP2968474B2 (ja) 1999-10-25
NO863974L (no) 1987-04-08
ES2053440T3 (es) 1994-08-01

Similar Documents

Publication Publication Date Title
IL80231A (en) Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
ZA833686B (en) Human human hybridomas for cervical carcinoma
NZ222309A (en) Antibodies (including chimeric antibodies) to a human tumour antigen, polynucleotides encoding them, detection of the antigen by immunoassay and imaging methods and also cell killing methods
FI853884A7 (fi) Monoklonaaliset, ihmisen rintasyöpää vastaan vaikuttavat vasta-aineet
ES8506091A1 (es) Un procedimiento para obtener un polidoma
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
EP0118365A3 (en) Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
DK40885D0 (da) Monoklonalt antistof, fremgangsmaade og celle til fremstilling deraf,fremgangsmaade til fremstilling af cellen og farmaceutisk praeparat indeholdende det monoklonale antistof
EP0210970A3 (de) Nachweis, Abbildung und Therapie von Nierenzellenkarzinomen mittels monoklonaler Antikörper
MX9605895A (es) Anticuerpos monoclonales humanos especificos para antigeno de superficie de glioma independiente del ciclo celular.
EP0155172A3 (de) Monoklonale Antikörper gegen menschlichen Lungenkrebs
AU5752490A (en) A novel tumor associated antigen
JPS6444856A (en) Anti-cancer antigen anti-serum
Hand et al. Potential Clinical Application of a Monoclonal Antibody to a Tumor Associated Glycoprotein (TAG-72)
ZA856281B (en) Monoclonal antibody to a human carcinoma tumor associated antigen

Legal Events

Date Code Title Description
KB Patent renewed
HC Change of name of proprietor(s)
RH Patent void